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Abstract
We describe the ﬁrst report of simultaneous blood infection
with KPC-2 producing Klebsiella pneumoniae and Escherichia coli
in a Brazilian patient. We highlight the importance of implement-
ing efﬁcient infection control measures to limit the spread of
these phenotypes in a hospital setting.
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The emergence and spread of carbapenem-resistant Entero-
bacteriaceae poses a major clinical and public health chal-
lenge. Of special concern are organisms that produce
Klebsiella pneumoniae carbapenemase (KPC)-type b-lactamase.
Subsequent to the initial report in 2001 [1], carbapenem
resistance mediated by production of KPC has been increas-
ingly identiﬁed in the USA and found to be widespread in
several regions around the world [2,3], including Brazil
[4–7]. Although KPCs are mostly identiﬁed from K. pneumo-
niae, KPC enzymes have now also been reported found in
many other Enterobacteriaceae [2,8–10]. However, the co-
infections is rarely described [8,10]. KPC may confer low-
level carbapenem resistance, and the failure of susceptibility
methods to identify this resistance has been reported [11].
The gene encoding the KPC enzyme is usually ﬂanked by
transposon-related sequences and has been identiﬁed on
conjugative plasmids; therefore, the potential for dissemina-
tion is signiﬁcant [12]. These KPC-producing bacteria are
predominantly involved in nosocomial and systemic infections
and have lead to an increase in the number of publications
concerning outbreaks caused by KPC bacteria production
[3,13–15]. In the present study, we describe the simulta-
neous blood infection with KPC-2 producing K. pneumoniae
and Escherichia coli in a Brazilian patient.
An 81-year-old female Brazilian patient was hospitalized in
a clinical ward of Hospital Universita´rio Pedro Ernesto, Rio
de Janeiro State, Brazil (tertiary-teaching Hospital with 600
beds and four intensive care units) with an initial diagnosis of
severe community-acquired pneumonia. Blood cultures were
collected on hospitalization and empiric intravenous antibi-
otic therapy was initialized with a combination of cefepime
1 g and vancomycin 1 g, both administered twice daily. The
patient had a medical history of end-stage renal disease in
replacement therapy with continuous ambulatory peritoneal
dialysis, probably due to hypertension. Because of the septic
state and increase in serum creatinine, haemodialysis was ini-
tialized on the third day of hospital stay using central venous
access by femoral puncture. During the 20-day hospital stay,
the patient had fever and leucocytosis and worsening of her
clinical condition. Catheter-related bloodstream infection
was suspected and line removal was realized. Catheter tip
culture and two sets of blood cultures showed ertapenem-
resistant E. coli and K. pneumoniae isolates. Antibiotic therapy
was changed to a combination consisting of intravenous
meropenem (1 g , 8/8 h) and intravenous amikacin (500 mg/
day for 14 days). The total time of hospital stay was 52 days
and, after line removal, she had a good evolution, with
recovery of normal respiratory parameters and oxygen con-
sumption. Although serum creatinine levels were diminished,
renal failure persisted and she was included in an ambulatory
programme of haemodialysis three times per week. Isolates
were screened using the modiﬁed Hodge test [11] in accor-
dance with the CLSI criteria [16]. Both isolates demon-
strated carbapenem hydrolysis using ertapenem as the test
substrate. The isolates showed positive PCR results using
blaKPC primers and amplicon sequencing revealed 100% of
sequence identity with blaKPC-2 [17]. Clinical sample 513LGB
[6] was used as control for the PCR assay. Using a disk
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diffusion test, both isolates were resistant to extended-spec-
trum cephalosporins, b-lactam/b-lactamase inhibitor combina-
tions, aztreonam and trimethoprim-sulphamethoxazole and
were susceptibile to amikacin and gentamicin. Both isolates
were susceptible to imipenem (IMP), meropenem (MER) and
resistance to ertapenem (ERT). Additionally, the MICs to
IMP, MER and ERT was obtained using an E-test (AB Biodisk,
Solna, Sweden). K. pneumoniae isolates exhibited resistance
to IMP, MER and ERT, with MIC above ‡32 mg/L. E. coli was
resistant to ERT (MIC = 8 mg/L) and susceptible to IMP and
MER (MIC = 2 mg/L and MIC = 0.38 mg/L, respectively).
The emergence of carbapenem resistance in Enterobacteri-
aceae requires careful monitoring [14]. The detection of such
strains by routine laboratory tests might be difﬁcult when
current standard antimicrobial susceptibility methods are
employed [18]. The occurrence of KPC-producing K. pneumo-
niae appears to be an emerging public health problem in vari-
ous parts of the world [8]. Brazil seems to represent a
country facing a similar widespread problem. Furthermore, it
is well recognized that these enzymes confer low level resis-
tance (i.e. lower than the established breakpoints) [19]. In
studies conﬁned to strains exhibiting a MIC value of IMP not
less than 1 mg/L, the possible presence of undetected strains
exhibiting lower MICs cannot be excluded and thus it is pos-
sible that the overall prevalence has been under-estimated.
These represent the major limitations to studying the exact
prevalence of the KPC-producing isolates in Brazil, as well as
the exact date of the ﬁrst isolation in each hospital. Data
from the Sentry antimicrobial surveillance programme report
of Latin American and Brazil show there has been an increase
in the resistance rates to IMP in K. pneumoniae during the last
decade [20]. General consumption of antibiotics in hospitals
in Brazil and of the newer b-lactam antibiotics is reported to
be at high levels. In the present case report, we report a spe-
cial co-existence between two Enterobacteriaceae species,
with the same carbapenemase-resistant type causing catheter-
related bloodstream infection. This infection was part of an
outbreak documented at the nephrology ward after possible
contamination from another hospital in a patient who was
infected after kidney transplantation (J. C. D. Correal, personal
communication). It highlights the importance of adhering to
the infection control practices, especially hand hygiene and
compliance with guidelines for the prevention of intravascu-
lar catheter-related infections [21]. It is important to note
that carbapenem resistance in E. coli does not occur natu-
rally, and acquired resistance is rare in these species [9].
Thus, K. pneumoniae is likely to represent a reservoir
of genetic transferable elements that confer this type of
resistance. Interestingly, there is another case report
describing bacteremia in a co-infection in a critically ill liver
transplant recipient with KPC-2 producing Enterobacter cloa-
cae and Pseudomonas putida [10]. We emphasize that there is
a real possibility that the transmissible KPC-2-encoding plas-
mid had spread amongst different genus and resulted in the
spread of the carbapenem resistance. Early detection and
implementation of strict infection control measures can help
to control the spread of carbapenem-resistant organisms in
healthcare facilities.
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Abstract
Studies suggest that infection with highly prevalent Pseudomonas
aeruginosa clones in cystic ﬁbrosis (CF) is associated with an
unfavourable clinical outcome. We studied the clinical character-
istics of patients infected with a recently described, highly preva-
lent P. aeruginosa clone (ST406) in two CF centres in The
Netherlands. Multilocus sequence typing data were available for
219 patients, of whom 40 (18.3%) were infected with ST406 and
179 with other sequence types. ST406 infection was indepen-
dently associated with age, having a sibling with ST406 infection
and use of inhaled antibiotics, but not with unfavourable clinical
outcome, suggesting that high transmissibility is not necessarily
associated with high virulence.
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Of patients with cystic ﬁbrosis (CF), 60–80% become chroni-
cally infected with Pseudomonas aeruginosa [1], which is asso-
ciated with increased morbidity and mortality [2]. The
original perception that each patient acquires his or her own
P. aeruginosa strain from the environment and that transmis-
sion only occurs in siblings with CF [3] is disputed by later
reports of the occurrence of highly prevalent clones of
P. aeruginosa in CF centres in Australia and Europe. Many of
these clones are highly resistant to antibiotics and appear to
be associated with unfavourable clinical outcome [4–8]. To
prevent the further spread of transmissible P. aeruginosa
clones, infection control policies and measures have been
put into practice in several countries [9,10]. Recently, a
cross-sectional study using multilocus sequence typing
(MLST) revealed a highly prevalent clone in the patient popu-
lation of two large CF centres in The Netherlands (together,
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